Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Summary

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous recombination defects (HRD).

Timeline

Start

2021-05-25

Primary completion

2027-05-31

Completion

2027-05-31

Drugs

Indications